Telix Pharmaceuticals Limited - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
TLX Nasdaq 2836 telixpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited Q2 2026 Earnings Call Summary - Aug 20th, 2026 6:35 pm
Telix Pharmaceuticals Ltd (TLPPF) (H1 2026) Earnings Call Highlights: Revenue Surges 22% to ... - Aug 20th, 2026 1:01 am
Telix Pharmaceuticals H1 Earnings Call Highlights - Aug 19th, 2026 7:02 pm
Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline - Aug 19th, 2026 6:02 pm
Telix to Host R&D Day in New York City on September 22, 2026 - Aug 5th, 2026 3:00 pm
Telix H1 2026 Results: Investor Webcast Notification - Jul 30th, 2026 4:41 pm
How Telix landed a $2.1 billion radiopharma deal with Regeneron - Jul 30th, 2026 3:12 am
Does Telix Pharmaceuticals Limited (TLX) Have the Potential to Rally 86.17% as Wall Street Analysts Expect? - Jul 22nd, 2026 7:55 am
TLX591-Tx ProstACT SELECT Study Published in Cancers Journal - Jul 21st, 2026 3:00 pm
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress - Jul 20th, 2026 5:31 pm
Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer - Jul 20th, 2026 3:00 pm
Telix Completes Patient Enrollment in TLX591-Px (Illuccix®) Japan Phase 3 Study - Jul 16th, 2026 4:00 pm
Telix opens radiopharmaceutical facility in Australia for cancer treatment - Jul 16th, 2026 4:12 am
Telix Opens Australian-First Facility to Accelerate Delivery of New Cancer Treatments and Expand Sovereign Manufacturing - Jul 15th, 2026 6:30 pm
First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer - Jul 15th, 2026 2:30 pm